$42.24
6.65% today
Nasdaq, Apr 02, 09:17 pm CET
ISIN
NL0011606264
Symbol
MRUS
Sector
Industry

Merus N.V. Stock price

$39.60
-5.87 12.91% 1M
-10.50 20.96% 6M
-2.45 5.83% YTD
-5.44 12.08% 1Y
+12.35 45.32% 3Y
+28.00 241.38% 5Y
+29.56 294.42% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-2.49 5.92%
ISIN
NL0011606264
Symbol
MRUS
Sector
Industry

Key metrics

Market capitalization $2.74b
Enterprise Value $2.21b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 61.12
P/S ratio (TTM) P/S ratio 75.73
P/B ratio (TTM) P/B ratio 4.21
Revenue growth (TTM) Revenue growth -17.78%
Revenue (TTM) Revenue $36.13m
EBIT (operating result TTM) EBIT $-272.07m
Free Cash Flow (TTM) Free Cash Flow $-184.90m
Cash position $537.73m
EPS (TTM) EPS $-3.32
P/E forward negative
P/S forward 67.79
EV/Sales forward 54.71
Short interest 11.72%
Show more

Is Merus N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Merus N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Merus N.V. forecast:

19x Buy
100%

Analyst Opinions

19 Analysts have issued a Merus N.V. forecast:

Buy
100%

Financial data from Merus N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
36 36
18% 18%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 78 78
42% 42%
216%
- Research and Development Expense 225 225
60% 60%
624%
-270 -270
75% 75%
-746%
- Depreciation and Amortization 2.47 2.47
3% 3%
7%
EBIT (Operating Income) EBIT -272 -272
74% 74%
-753%
Net Profit -215 -215
39% 39%
-596%

In millions USD.

Don't miss a Thing! We will send you all news about Merus N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Merus N.V. Stock News

Neutral
GlobeNewsWire
one day ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 24th An...
Neutral
GlobeNewsWire
about one month ago
-  Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25
Neutral
GlobeNewsWire
about one month ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
More Merus N.V. News

Company Profile

Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.

Head office Netherlands
CEO Bill Lundberg
Employees 260
Founded 2003
Website www.merus.nl

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today